Arctic Bioscience presents HeROPA data at EADV in Athens
Arctic Bioscience is presenting key results from the HeROPA study at the European Academy of Dermatology and Venereology (EADV) Symposium in Athens, Greece, 7-9th May 2026. The data shows statistically significant difference in key psoriasis endpoints compared to placebo in patients with lower baseline systemic immune-inflammatory index (SII), while no such difference was observed in patients with higher baseline SII.
The poster "Beyond skin deep: Baseline systemic immune-inflammatory index as predictor of treatment response of HRO350 in mild-to-moderate psoriasis. Results from the HeROPA study", shows that patients with SII at or below the median had greater response to HRO350 compared to placebo across several endpoints in the per-protocol population. In contrast, patients with SII above median showed no benefit from HRO350 compared to placebo and this group showed tendencies for higher placebo rates.
Differences in response rates between the low and high SII groups exceeded 25 percentage points for several skin symptom endpoints and were statistically significant.
The safety data derived from this study, which included over 500 patients, shows a favorable safety and tolerability profile for HRO350.
Coordinating investigator for the HeROPA trial, Professor Ingeborg Bachmann from Haukeland University Hospital, is first author of the poster.
"It is very positive that we are presenting results from the HeROPA study at such a prestigious scientific event. As a Norwegian biotech company, it is a major milestone to conduct and complete a phase 2b clinical trial of this size. This publication, and other future publications from the study, will support the ongoing partnering dialogues for future development of HRO350", says CEO Christer Valderhaug.
"It is a milestone and an honor to present data from the HeROPA study at the EADV Symposium. We have used SII as a biomarker to look at how high inflammatory load the patients had, and this has helped us understand the data from the study. Inflammation is a key driver for psoriasis, and these data show that the patients with a less severe inflammation in the blood respond best to HRO350, which supports the positioning of HRO350 in mild-to-moderate psoriasis. I am very grateful to the patients who participated, and it is my hope that the results can contribute to treatment advances for patients with mild-to-moderate psoriasis, who have so few treatment options today" says medical director Runhild Gammelsæter, who attends the EADV in Athens.
Reference:
Bachmann I, Ringheim-Bakka T, Meland N, Smerud K, Kirby B, Gammelsaeter R. "Beyond skin deep: Baseline systemic immune-inflammatory index as predictor of treatment response of HRO350 in mild-to-moderate psoriasis. Results from the HeROPA study". Poster ID P1125, Abstract ID-727, EADV Symposium, Athens, Greece, May 7-9th, 2026.
The poster will also be made available on the IR tab on the company's webpage.
For further information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.